Itolizumab for Injection

ITOVIT for Injection is a monoclonal antibody that targets the CD6 receptor on T-cells, modulating immune response and inflammation. It is used primarily in the treatment of autoimmune diseases. The main uses of ITOVIT for Injection include:

1. Treatment of Moderate to Severe Plaque Psoriasis:

   - ITOVIT was initially developed for and is primarily used to treat moderate to severe chronic plaque psoriasis, a condition characterized by the rapid growth of skin cells leading to scaling and inflammation.

2. Management of Cytokine Release Syndrome (CRS) in COVID-19:

   - During the COVID-19 pandemic, ITOVIT was repurposed and used under emergency authorizations in some countries to manage cytokine release syndrome (CRS) in patients with moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19. CRS is a hyperinflammatory condition that can lead to severe complications in COVID-19 patients.

3. Treatment of Autoimmune Diseases:

   - While primarily approved for psoriasis, ITOVIT is being explored for the treatment of other autoimmune conditions, such as rheumatoid arthritis, lupus, and multiple sclerosis, due to its ability to modulate the immune response.

4. Potential Use in Organ Transplantation:

   - There is ongoing research into using ITOVIT to prevent organ transplant rejection by reducing T-cell mediated immune responses.

ITOVIT for Injection is administered intravenously under the supervision of a healthcare professional. The dosage and frequency depend on the condition being treated, and patients are monitored for potential side effects, including infusion reactions, infections, and immunosuppression.